3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
93
Recurrence
16
Neoplasms
10
Lymphoma, Non-Hodgkin
5
Leukemia, Myeloid, Acute
4
Neoplasms, Plasma Cell
3
Hematologic Neoplasms
3
Smoldering Multiple Myeloma
2
Plasmacytoma
2
Lymphoma, Large B-Cell, Diffuse
2
Carcinoma, Non-Small-Cell Lung
2
Various Advanced Cancer
1
Triple Negative Breast Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Personal Satisfaction
1
Patient Satisfaction
1
Patient Preference
1
Pancreatic Neoplasms
1
Myelodysplastic Syndromes
1
Microsatellite Unstable Colorectal Cancer
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell
1
Lymphoma
1
Immunoglobulin Light-chain Amyloidosis
1
Hodgkin Disease
1
Hematologic Diseases
1
Disease
1
Amyloidosis
1
Interventions
pertuzumab
1
pazopanib
1
decitabine and cedazuridine drug combination
1
daratumumab
1
Trastuzumab
1
Surgical Procedures, Operative
1
Sunitinib
1
Sorafenib
1
Radiotherapy
1
Opdualag
1
Nivolumab
1
Injections, Subcutaneous
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Patient Preference
×
daratumumab
×
Clear all
NCT05284591
2024-10-01
MYLENE
iOMEDICO AG
Completed
96 enrolled